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Invasive pulmonary aspergillosis (IPA), characterized by hyphal invasion and destruction of pulmonary tissue, is a frequent opportunistic infection in patients receiving allogeneic stem cell transplantation (SCT) with an incidence of nearly 10%. 1 The important predisposing conditions for IPA are known to be neutropenia, 2 intensive immunosuppression, and graft-versus-host disease (GVHD). 3 In terms of host immunity toward IPA, including innate and acquired immunity, 1, 4 the roles of several cytokines are known to be associated with the pathogenesis of IPA. The protective role of type 1 response cytokines, such as interferon-gamma and TNF-alpha, has been already established. 5, 6 However, the role of IL-10, a typical Th2 regulator cytokine, is still under debate. 1 Generally, an increased production of IL-10 is known to correlate with susceptibility to IPA. For example, IL-10 pretreated human macrophages were found to suppress superoxide production and decrease hyphal damage, thus increasing the risk of IPA.
IL-10 is known to play various roles in immune-regulating and antiinflammatory responses, 7, 8 plus the IL-10 promoter gene single nucleotide polymorphism (SNP) may affect the transcription of the IL-10 genes. 9 Furthermore, a certain haplotype has been associated with an increased production of the IL-10 cytokine. 9 Recently, the IL-10 promoter gene SNP was found to be associated with acute 10 or chronic GVHD, 11, 12 or transplant-related mortality (TRM) in an allogeneic transplant setting. 13 Moreover, the role of IL-10 in the local host defense mechanism in the lungs may also affect the pathogenesis of IPA.
14 However, data on the association of the IL-10 promoter gene SNP with the pathogenesis of IPA after allogeneic SCT is scarce. Accordingly, the current study attempted to evaluate the role of the IL-10 promoter gene SNP in the occurrence of IPA after allogeneic SCT.
Materials and methods

Patient characteristics and transplantation procedure
A total of 105 consecutive adult patients who had undergone allogeneic SCT at Kyungpook National University Hospital (Daegu, Korea) between Aug 1998 and October 2004 were included in this retrospective study. The enrolled hematological diseases included acute myeloid leukemia (AML, n ¼ 50, 48%), acute lymphoblastic leukemia (ALL, n ¼ 14, 13%), chronic myeloid leukemia (CML, n ¼ 16, 15%), myelodysplastic syndrome (MDS, n ¼ 5, 5%), severe aplastic anemia (AA, n ¼ 10, 9%), non-Hodgkin's lymphoma (NHL, n ¼ 6, 6%), multiple myelomas (MM, n ¼ 2, 2%), and other diseases (paroxysmal nocturnal hemoglobinuria, n ¼ 1 and metastatic colorectal cancer, n ¼ 1; 2%) with 56 in a standard disease status (53%) and 49 in an advanced disease status (47%).
The conditioning regimens consisted of busulfan/cyclophosphamide (n ¼ 68, 65%), a fludarabine-based regimen (n ¼ 27, 26%), and cyclophosphamide/antithymocyte globulin (ATG; n ¼ 10, 9%). The fludarabine-based regimen was as follows: (1) fludarabine, busulfan, and cyclophosphamide7ATG (n ¼ 10), (2) fludarabine, idarubicin, and cytarabine (n ¼ 5), (3) fludarabine and cyclophosphamide7ATG (n ¼ 8), and (4) fludarabine and busulfan7ATG (n ¼ 4). Among the 105 patients, two cases with a previous history of invasive fungal infection received a reducedintensity conditioning regimen without ATG.
Apheresis procedures were performed in 79 patients (75%), all from related donors, as previously described, 15, 16 while the remaining 26 patients (25%) received a marrow harvest from related (n ¼ 11) or unrelated donors (n ¼ 15) as the source of stem cells. The prophylaxis against acute GVHD consisted of methotrexate (MTX) and cyclosporin A (CSA; Cipol-N s , ChongKunDang, Seoul, Korea), except for seven cases treated with CSA alone (n ¼ 3) or FK506 plus short MTX (n ¼ 4). An antithymocyte globulin (ATG) infusion was conducted in 35 patients (33%) as partial conditioning for AA (n ¼ 10) or a partially mismatched or unrelated SCT (n ¼ 12) or reduced-intensity conditioning regimen (n ¼ 13).
The infection prophylaxis consisted of ciprofloxacin (250 mg bid p.o.)/metronidazole (500 mg tid p.o.)/fluconazole (100 mg qd p.o.), beginning with the initiation of conditioning, and acyclovir (600 mg bid p.o.) from day À1 until day þ 180. Co-trimoxazole was started after engraftment, and ursodeoxycholinic acid used for the venoocclusive disease prophylaxis, beginning with the initiation of conditioning. Intravenous immunoglobulin (500 mg/kg) was infused every two weeks until day 100, and every month up until 6 months. All patients received irradiated blood products that had been depleted of leukocytes using filters, and were isolated in rooms with high-efficiency particulate air (HEPA) filtration and laminar air-flow ventilation during their admission period. Acute and chronic GVHD were diagnosed and graded using established criteria. 17, 18 Diagnosis and treatment of IPA To monitor for pulmonary problems, a high-resolution computed tomographic examination was routinely performed. In patients with pulmonary infiltrates, a sputum smear and culture for bacteria, fungi, and Mycobacterium tuberculosis were carried out following bronchoscopic washing and brushing. In patients with focal pulmonary lesions, a radiologically guided fine-needle biopsy was used as the first-line diagnostic procedure. 19 The diagnosis of IPA was performed using EORTC/ MSG diagnostic criteria as follows. 20 A proven diagnosis of IPA was based on the demonstration of hyphae with microscopy from tissue samples taken with or without a positive culture for Aspergillus sp. A probable diagnosis of IPA was the demonstration of hyphae and/or a positive culture for Aspergillus sp from specimens taken at the time of bronchoscopic washing and brushing in patients with radiologically suggestive pulmonary fungal infections. A possible diagnosis of IPA was based on radiologically suggestive pulmonary fungal infections and positive clinical symptoms/signs.
The initial treatment of IPA was with systemic itraconazole (200 mg intravenously twice a day for 2 days, followed by 200 mg intravenously once a day for 7 days). If no improvement was observed in the pulmonary infiltrates, amphotericin B intravenous treatment was started immediately. Maintenance treatment with oral itraconazole (100 mg, four times a day) then followed after an improvement in the pulmonary lesions resulting from the systemic itraconazole or amphotericin B treatment.
IL-10 promoter gene polymorphism study
Three single-nucleotide polymorphisms in the proximal region of the IL-10 promoter gene were investigated in the current study: Peripheral blood samples were taken from the transplant recipients before the conditioning treatment under informed consent. Genomic DNA was then extracted from the blood samples using a Wizard genomic DNA purification kit (Promega, Madison, WI, USA).
Three biallelic IL-10 promoter polymorphisms were detected based on a polymerase chain reaction (PCR) using primers that amplified a short fragment of the DNA containing the polymorphic sites. The primer sequences used in the present study were as previously described 12 : For the À1082 polymorphism, 5 0 -CTCGCTGCAACC CAACTGGC-3 0 and 5 0 -TCTTACCTATCCCTACTTCC-3 0 ; À819 polymorphism, 5 0 -TCATTCTATGTGCTGGAGA TGG-3 0 and 5 0 -TGGGGGAAGTGGGTAAGAGT-3 0 ; and À592 polymorphism, 5 0 -CCTAGGTCACAGTGACGT GG-3 0 and 5 0 -GGTGAGCACTACCTGACTAGC-3 0 . The products obtained from these three reactions had 139, 209, and 412 base pairs. The DNA from patients whose IL-10 promoter sequences at the 1082, 819, and 592 sites were determined by direct sequencing was used for the positive controls. The amplifications were performed on a GeneAmp s PCR System 9700 (Applied Biosystems, Foster city, CA, USA) in a 20 ml reaction mixture containing 1 mg of template DNA, 10 mM Tris-HCl (pH 9.0), 40 mM KCl, 1.5 mM MgCl 2 , 250 mM each of dNTP, 20 pM of each primer, and 1 U of Taq polymerase (Bioneer, Korea). The following three cycling conditions were used: first at 941C for 7 min; second, 30 cycles at 941C for 45 s, 601C for 45 s, and 721C for 60 s; and third, at 721C for 10 min.
The restriction enzymes MnlI (New England Biolabs Inc., Beverly, MA, USA) for the À1082 loci, MaeIII (Roche Diagnostics Corp., Penzberg, Germany) for the À819 loci, and RsaI (Roche Diagnostics) for the À592 loci were used to distinguish the SNPs. PCR products (5 ml) was digested overnight with 5 U of MnlI (À1082) for 2 h at 371C MaeIII (À810) for 1 h at 551C, and RsaI (À592) 1 h at 371C. The digestion products were then separated on a 6% acrylamide gel. Selected PCR-amplified DNA samples were examined by DNA sequencing to confirm the genotyping results. The current study was approved by the Institutional Research Board of Kyungpook National University Hospital and each patient gave written informed consent.
Statistics
The results were analyzed according to information available as of January 2005. The clinical characteristics and transplant outcomes for the patients were compared using a w 2 test, Fisher's exact test, or Mann-Whitney's Utest according to the development of IPA, as appropriate. The Hardy-Weinberg equilibrium for an IL-10 polymorphism was tested using a w 2 analysis. The haplotypes were determined based on a Bayesian algorithm using the Phase program 21 (available at http://www.stat.washington.edu/ stephens/phase.html).
In terms of the survival analysis, the onset of IPA was defined as the day when the clinical symptoms or signs of IPA were first reported, while the duration of the development of IPA was defined as the interval from the date of transplantation to the onset of IPA. The cumulative incidence of IPA was estimated using the Kaplan-Meier method. A Wilcoxon test was also used for the survival analyses based on the IL-10 promoter gene haplotypes.
To identify the predictive factors for the development of IPA after allogeneic SCT, a time-dependent Cox proportional hazard model was adopted considering the timedependent effect of chronic GVHD using a backward conditioning procedure until the P-value for the likelihood ratio test was 40.05, and hazard ratio (HR) and 95% confidence intervals (CI) were calculated. The variables included for the analyses of the incidence of IPA were timedependent chronic GVHD, the mononuclear (o6 vs X6 Â 10 8 /kg) and CD34 þ cell dose (o6 vs X6 Â 10 6 /kg), conditioning (myeloablative vs reduced-intensity conditioning), use of ATG, donor type (histocompatibility leukocyte antigen (HLA)-identical sibling or unrelated donor vs other alternative donor), source of stem cells (peripheral blood stem cells vs bone marrow), and IL-10 promoter gene SNPs (ACC haplotype vs non-ACC haplotype). A cut off P-value of 0.05 was adopted for all statistical analyses. The statistical data were obtained using an SPSS software package (SPSS 10.0 Inc. Chicago, IL, USA).
Results
Patient characteristics and transplantation outcomes
The patient characteristics are summarized in Table 1 . The median age of the patients was 34 years (range, 16-58 years), and the female to male ratio was 35:65% (n ¼ 37 and 68). The infused median doses of mononuclear, CD34 þ , and CD3 þ cells were 7.07 Â 10 Table 2 . Briefly, the frequency of acute and chronic GVHD was 77 (79%) out of 98 evaluated cases and 65 (77%) out of 84 evaluated cases, respectively. Out of the total 105 cases, 57 patients (54%) died of non-relapse mortality (n ¼ 39, 37%) or progressive disease (n ¼ 19, 17%).
Incidence and clinical outcomes of IPA
With a median follow-up duration of 292 days (range 9 to 2076 days), 9 events of IPA were observed. A summary of each IPA case is presented in Table 3 . The cumulative incidence of IPA was estimated as 14.174.5% with a median onset at 186 days (range 62B405 days; Figure 1a) . The median duration of survival after the diagnosis of IPA was 394 days, and four patients died of respiratory failure due to IPA (n ¼ 3) or concomitant CMV pneumonia (n ¼ 1).
The development of IPA was found to be associated with the donor type (P ¼ 0.001), source of stem cells (P ¼ 0.025), CD34 þ transplant cell dose (P ¼ 0.004), and use of ATG (P ¼ 0.003; Table 1 ). Among the post-transplant events, no differences were observed between the groups with or without IPA as regards the occurrence of acute GVHD, extensive chronic GVHD, relapse, or death, including non-relapse mortality ( Table 2 ). The incidence of chronic GVHD showed a higher trend in the group with IPA (100%) than in the group without IPA (75%; P ¼ 0.086), yet only a marginal statistical significance.
Frequency of IL-10 promoter gene SNPs
The genotype frequencies of the three polymorphisms of the IL-10 promoter gene showed a significant deviation from the Hardy-Weinberg expectation. Among total 101 patients, the distribution of the IL-10 promoter gene SNPs at À1082, À819, and À592 are as follows: All patients exhibited a monomorphic pattern at -1082. The frequency of the CC, CT, and TT-genotype at -819 was 11, 47, and 42%, respectively, while the frequency of the CC, CA, and AA-genotype at À592 was 11, 47, and 42%, respectively. Therefore, the current cohort revealed two predominant haplotypes: -1082*A/À819*T/À592*A (ATA) with an estimated frequency of 65.2% and À1082*A/À819*C/ À592*C (ACC) with an estimated frequency of 34.8%.
IL-10 promoter gene SNPs and IPA
When comparing the patients according to their IL-10 promoter gene haplotypes, the incidence of IPA was lowest in the patients with the ACC/ACC haplotype (0%) when compared to the patients with the ACC/ATA (11.576.4%) or ATA/ATA haplotype (19.777.7%; P ¼ 0.2734) in a dose-dependent manner (Figure 2a ). In particular, the patients with the ACC haplotype showed a lower incidence of IPA than those without the ACC haplotype (P ¼ 0.0307; Figure 2b) .
When confining the analysis to those patients that received an SCT from an HLA-identical sibling or unrelated donor to exclude the influence of HLA-disparity, IL-10 SNP in IPA after alloSCT KW Seo et al similar outcomes were also observed. Among the 11 patients with the ACC/ACC haplotype, none developed IPA after SCT, while two and five events of IPA were observed among the 44 patients with the ACC/ATA haplotype and the 39 patients with the ATA/ATA haplotype, respectively. Moreover, the protective role of the ACC haplotype was also noted: the incidence of IPA was 5.3% in the patients with the ACC haplotype, while 18.2% in the patients with the non-ACC haplotype (P ¼ 0.0217).
To identify the predictive factors for the development of IPA after allogeneic SCT, a time-dependent Cox proportional hazard model was adopted considering the time-dependent effect of chronic GVHD, as previously mentioned in Statistics. In a multivariate survival analysis (Table 4) , the patients with the ACC haplotype showed a lower incidence of IPA than those without the ACC haplotype (P ¼ 0.012, hazard ratio (HR) 9.260 (1.623B52.839)), together with an HLA-identical donor (P ¼ 0.005, HR 16.303 (2.300B115.562)), higher infused dose of CD34 þ cells (P ¼ 0.004, HR 26.503 (2.911B241.266)), and time-dependent chronic GVHD (P ¼ 0.049, HR 16.025 (1.018B252.310)).
Discussion
The current study addressed the protective role of the IL-10 ACC haplotype as regards the occurrence of IPA after allogeneic SCT, since there is a lack of human data on cytokine gene SNPs in relation to the development of IPA.
IPA is a frequent opportunistic infection with an average incidence of 5 to 10% in patients receiving allogeneic SCT, and is diagnosed based on histopathologic evidence of mycelial growth in lung tissue, characterized by hyphal invasion and destruction of pulmonary tissue. The defense mechanism by innate immunity involves pulmonary alveolar macrophages that recognize, bind, and ingest the conidia of A. fumigatus, thereby eliminating the conidia through the typical phagocytic activity of alveolar macrophages. 4 Meanwhile, the other defense mechanism against hyphae is related to the function of the neutrophils. The predisposing factors to IPA include transplantationassociated factors, such as prolonged neutropenia, 2 intensive immunosuppression, or GVHD3 in an allogeneic transplant setting. In addition, factors related to the defense mechanism of the host against A. fumigatus would also seem to be involved in the pathogenesis of IPA. In terms of host immunity toward IPA, the roles of several cytokines have already been associated with the development of IPA, where the protective role of a type-1 response cytokine, such as interferon-gamma and TNF-alpha, has already been established. TNF-alpha is known to enhance the antifungal activity of polymorphonuclear neutrophils and mononuclear phagocytes against A. fumigatus. However, the role of IL-10, a typical Th2 regulatory cytokine, is still under debate. The progression of IPA has been associated with a Th2 response, correlating to an increase in the IL-4 and IL-10 levels and decrease in the level of IFN-gamma. For example, IL-10 pretreated human macrophages have been found to suppress superoxide production and decrease hyphal damage, thus increasing the risk of IPA, 22 while IL-10 deficient mice exhibit an upregulated antifungal response and increased resistance to lethal systemic aspergillosis. 23, 24 Furthermore, in cortisonepretreated mice, A. fumigatus has been found to cause Years from transplantation IL-10 SNP in IPA after alloSCT KW Seo et al lethal invasive aspergillosis with high expression levels of IL-10 in the lungs. 25 Therefore, these results indicate that IL-10 plays a negative role as regards invasive aspergillosis in mice models. Meanwhile, in a human study, Roilides et al 26 reported a correlation between the serum IL-10 concentrations and IPA outcomes in non-neutropenic immunocompromised patients, with favorable outcomes for patients with low IL-10 concentrations and devastating outcomes for patients with high IL-10 concentrations.
Recent systematic screening of the IL-10 promoter gene has identified multiple single nucleotide SNPs, 9 some of which appeared to be associated with IL-10 production. However, conflicting results have been reported regarding the genetic control of IL-10 production. In a study based on a Caucasian population, the ACC haplotype seemed to be associated with lower IL-10 production rather than the GCC or ATA haplotype, 9 ,27 yet this was not found with other ethnicities. 28 In another study of IL-10 promoter gene SNPs and their effect on the transcription of IL-10 mRNA following stimulation with Streptococcus pneumoniae, the ATA haplotype produced more IL-10 mRNA than the ACC and GCC haplotypes after lipopolysaccharide stimulation. 29 The increased production of IL-10 mRNA by the ATA haplotype has been explained based on the increased stimulation of transcriptional activity by the higher binding capacity of the -819T and -592 alleles to the transcription factor. Nonetheless, further studies are required to address whether the ACC haplotype has the ability to increase IL-10 mRNA expression using in vitro cell-based assays.
In the current study, the ACC haplotype was found to reduce the risk of IPA 9-fold. Although the serum IL-10 level was not measured in the present study, the IL-10 ACC haplotype did appear to have a protective impact on the development of IPA after allogeneic SCT. Accordingly, pretransplant cytokine gene profiling of IL-10 or other candidate genes, such as TNF-alpha or interferon-gamma, may facilitate a more individually tailored prophylaxis or emphasize monitoring for IPA after allogeneic SCT in patients with a high risk of IPA-prone genotypes.
In conclusion, the present findings suggested that the IL-10 ACC haplotype was associated with the occurrence of IPA after allogeneic SCT. However, further study is required to reach a final conclusion on the association of IL-10 promoter gene SNPs with IPA after allogeneic SCT. For the analysis, the IL-10 promoter gene SNPs (ACC versus non-ACC haplotype), transplanted dose of CD34+ cells (6 Â 10 6 /kg) and mononuclear cells (6 Â 10 6 /kg), source of stem cells (PBSC versus BM), donor (HLA-identical sibling or unrelated donor versus other), conditioning (RIST versus myeloablative), use of ATG, and time-dependent chronic GVHD were included.
